Other grades of this product :
| Levosimendan Basic information |
| Product Name: | Levosimendan | | Synonyms: | LEVOSIMENDAN;-2-[[4-(1，4，5，6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)19henyl]hydrazono]Propandinitrile;(R)-Simendan;[[4-[(4R)-1,4,5,6-Terahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazono]propanedinitrile;OR-1259;Simda;Mesoxalonitrile (-)-{p-[(R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl}hydrazone;(R)-2-[[4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL] HYDROZONO]PRO | | CAS: | 141505-33-1 | | MF: | C14H12N6O | | MW: | 280.28 | | EINECS: | 663-528-6 | | Product Categories: | Inhibitors;FLUOTHANE;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 141505-33-1.mol |
| Levosimendan Chemical Properties |
| Melting point | 216-219°C (dec.) | | alpha | D25 -566° (tetrahydrofurane/methanol) | | density | 1.33±0.1 g/cm3(Predicted) | | storage temp. | room temp | | solubility | DMSO: ≥20mg/mL | | pka | 6.3(at 25℃) | | form | powder | | color | yellow | | optical activity | [α]/D -500 to -650°, c = 0.5 in THF |
| Hazard Codes | Xn | | Risk Statements | 20/21/22 | | Safety Statements | 36/37 | | WGK Germany | 3 | | RTECS | TY1570210 | | Toxicity | LD50 in male, female mice, male rats (mg/kg): 156, 152, 103 orally; 32, 50, 57 i.v. (Pagel) |
| Levosimendan Usage And Synthesis |
| Description | Levosimendan was introduced in Sweden as an i.v. infusion for the treatment of acute
heart failure or refractory symptoms of chronic heart failure in cases where conventional
treatment (e.g., diuretic or ACE inhibitor) is not sufficient. Levosimendan is the (R)-
enantiomer of simendan that belongs to the same class as pimobendan (Boehringer
Ingelheim). Levosimendan is an innovative myofilament calcium sensitizer that increases
myocardial contractility by selectively binding to the N-terminus of troponin C and by
stabilizing the Ca2+-bound conformation of this contractile protein. It also activates
ventricular and arterial adenostne triphosphate-regulated potassium channels which
causes vasodilatation in vascular smooth muscle and protects myocardium against
infarction. Its low phosphodiesterase III inhibiting activity is probably not responsible for its
positive inotropic, lusitropic and dilating effects. Unlike other cardiotonic drugs,
levosimendan is able to produce positive inotropic effects without prolonging myocardial
relaxation or increasing the incidence of malignant arrythmias. It was clinically shown to
have a lower risk of mortality in patients with heart failure when compared to placebo and
dobutamine. Since it has a larger potential, levosimendan is currently under further clinical
evaluation as a chronic treatment for congestive heart failure. | | Description | Levosimendan is a calcium sensitizer that can cause increased cardiac contractility by binding troponin C (EC50 = 9 nM), promotes vasodilation by activating ATP-sensitive potassium channels on vascular smooth muscle cells (EC50 = 0.28 μM), and performs a cardioprotective function by prompting the opening of mitochondrial potassium channels in cardiomyocytes. It also has been reported to inhibit phosphodiesterases 3 and 4 in left ventricular cardiac tissue with IC50 values of 2.5 nM and 25 μM, respectively. | | Chemical Properties | Yellow Crystalline Powder | | Originator | Orion (Finland) | | Uses | Levosimendan has been used for screening its anti-human immunodeficiency virus type 1 (HIV-1) property. It has also been used for screening its cytotoxic effects in TP53 mutant and wild-type lung adenocarcinoma cell lines | | Uses | Bioactive enantiomer of racemate, Simendan. Positive inotropic agent with vasodilating activity. Cardiotonic | | Uses | anesthetic | | Uses | Levosimendan is a positive inotropic agent that acts by sensitising troponin
C to Ca2+, prolonging actin-myosin cross-bridge formation and therefore
increasing contractility. This is an energy-independent process and therefore
does not increase myocardial oxygen demand. Levosimendan also causes
vasodilatation by opening ATP-sensitive K+ channels in vascular smooth
muscle, reducing pre- and afterload and improving myocardial oxygen
supply. It may have a role in the management of acute heart failure and
postresuscitation myocardial dysfunction. | | Brand name | Simdax (Orion Pharmaceutica,
Finland). | | Biochem/physiol Actions | Levosimendan has a potential to inhibit both acute human immunodeficiency virus type 1 (HIV-1) replication and the reactivation of latent HIV-1 proviruses. Therefore, it is considered to be a promising anti-HIV-1 agent. |
| Levosimendan Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye